somatorelin Report issue

Biologics Peptide Experimental
AACT ChEMBL DrugBank Drug Central KEGG PubChem

Active Ingredient History

NOW
  • Now
Growth hormone–releasing hormone (GHRH), also known as somatocrinin or by several other names in its endogenous forms and as somatorelin (INN) in its pharmaceutical form, is a releasing hormone of growth hormone (GH). It is a 44-amino acid peptide hormone produced in the arcuate nucleus of the hypothalamus.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

ghrh | ghrh ferring | growth hormone releasing hormone | somatorelin | somatorelin acetate

Organizations (15)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Aged (Phase 2)

Aging (Phase 2)

Cognitive Dysfunction (Phase 1)

Growth Hormone (Phase 2)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 2)

Hormones (Phase 2)

Infertility (Phase 3)

Obesity, Abdominal (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue